Beta Glucosylceramide for Treatment of NASH

Status Completed

Clinical Trial Summary

Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.

Clinical Trial Description

Patients with NASH to receive the treatment versus placebo for 40 weeks followed by a liver biopsy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Compliance Behavior

Clinical Trial Details

NCT number	NCT02126306
Study type	Interventional
Source	Hadassah Medical Organization
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 2006
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01470222` - The Healthy Weight for Life Program	N/A
Completed	`NCT01752595` - The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment	N/A
Enrolling by invitation	`NCT02653781` - Implementation of Realistic Simulation as Patient Safety Improvement Method	N/A
Completed	`NCT02206893` - Evaluating Consumer m‐Health Services for User Engagement and Health Promotion: An Organizational Field Experiment	N/A
Completed	`NCT02758054` - Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System	N/A
Recruiting	`NCT01477385` - Treatment of Initial Caries Lesions on Proximal Surfaces of Primary and Permanent Posterior Teeth	N/A
Completed	`NCT02124031` - Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis (IMPACTAR)	N/A